
Benzinga Pro data, Atara Biotherapeutics (NASDAQ:ATRA) reported Q4 sales of $7.55 million. Earnings fell to a loss of $93.35 million, resulting in a 10.26% decrease from last quarter. Atara Biotherapeutics collected $5.37 million in revenue during Q3, but reported earnings showed a $84.66 million loss.